Get the Stockscreener App
0.8542
3.91%
-0.0348
After Hours:
.86
0.0058
+0.68%
Neurosense Therapeutics Ltd stock is traded at $0.8542, with a volume of 60,272.
It is down -3.91% in the last 24 hours and down -1.82% over the past month.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
See More
Previous Close:
$0.889
Open:
$0.8605
24h Volume:
60,272
Relative Volume:
0.24
Market Cap:
$28.53M
Revenue:
-
Net Income/Loss:
$-10.21M
P/E Ratio:
-1.4622
EPS:
-0.5842
Net Cash Flow:
-
1W Performance:
-5.28%
1M Performance:
-1.82%
6M Performance:
-27.61%
1Y Performance:
-25.72%
1-Day Range:
$0.82
$0.8851
1-Week Range:
$0.8127
$0.9198
52-Week Range:
$0.6801
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Name
Neurosense Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare NRSN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.8542 | 29.69M | 0 | -10.21M | 0 | -0.5842 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Neurosense Therapeutics Ltd Stock (NRSN) Latest News
Revenue Check: Is NeuroSense Therapeutics Ltd Equity Warrant forming a bullish divergence2025 Technical Patterns & Verified Momentum Stock Ideas - baoquankhu1.vn
IANS - IANS
Book value per share of Neurosense Therapeutics Ltd. – FWB:H1Z - TradingView
Buyback Watch: Is NeuroSense Therapeutics Ltd Equity Warrant stock undervalued right now2025 Market WrapUp & Verified Momentum Watchlists - baoquankhu1.vn
NRSN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Panic Selling: Is NeuroSense Therapeutics Ltd still a buy after recent gains2025 Buyback Activity & Daily Volume Surge Signals - baoquankhu1.vn
Activity Recap: Is NeuroSense Therapeutics Ltd Equity Warrant stock undervalued right nowJuly 2025 Reactions & Long-Term Safe Investment Plans - baoquankhu1.vn
Earnings Miss: What is VCICs valuation compared to sector2025 Momentum Check & Real-Time Price Movement Reports - baoquankhu1.vn
Gap Down: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesTrade Exit Summary & Weekly High Return Stock Forecasts - baoquankhu1.vn
Why is NeuroSense Therapeutics Ltd. stock going downMarket Volume Summary & Daily Risk Controlled Trade Plans - mfd.ru
What are NeuroSense Therapeutics Ltd. Equity Warrant’s recent SEC filings showingStop Loss & Weekly High Conviction Ideas - mfd.ru
ALS drug PrimeC cuts death risk by 65% - Longevity.Technology
Is NeuroSense Therapeutics Ltd. Equity Warrant stock safe for conservative investorsPortfolio Value Report & Long-Term Safe Investment Ideas - mfd.ru
Aug Chart Watch: Does NeuroSense Therapeutics Ltd Equity Warrant align with a passive investing strategyJuly 2025 Opening Moves & Safe Capital Investment Plans - baoquankhu1.vn
NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis - MarketBeat
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS - Finviz
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
NeuroSense Reports 65% Lower Mortality Risk and 14-Month Survival Gain for PrimeC in ALS Trial - TipRanks
Published on: 2026-02-18 21:38:58 - baoquankhu1.vn
ALS trial: NeuroSense drug extends survival by 14 months, cuts deaths 65% - Stock Titan
Buyout Rumor: Whats the analyst consensus on Invesco Mortgage Capital IncPortfolio Gains Report & Weekly High Return Stock Forecasts - baoquankhu1.vn
How NeuroSense Therapeutics Ltd. stock reacts to global recession fearsJuly 2025 Short Interest & Verified Stock Trade Ideas - mfd.ru
NRSN Should I Buy - Intellectia AI
What are the risks of holding NeuroSense Therapeutics Ltd. Equity WarrantWeekly Earnings Recap & Reliable Volume Spike Trade Alerts - mfd.ru
NeuroSense Provides Business Update and Progress for the First Half of 2025 - Intellectia AI
Why NeuroSense Therapeutics Ltd. Equity Warrant stock could be next big winner2025 EndofYear Setup & Weekly High Return Forecasts - mfd.ru
Is NeuroSense Therapeutics Ltd. stock supported by strong fundamentalsPortfolio Gains Summary & Weekly High Conviction Trade Ideas - mfd.ru
Will NeuroSense Therapeutics Ltd. (H1Z) stock enhance shareholder valueWeekly Investment Report & Pattern Based Trade Signal System - mfd.ru
NeuroSense Therapeutics Calls March 10, 2026 Special Meeting to Approve Share Capital Increase - TipRanks
Published on: 2026-02-13 23:05:19 - baoquankhu1.vn
Is NeuroSense Therapeutics Ltd. a momentum stock2025 Technical Patterns & Weekly Top Gainers Alerts - mfd.ru
Aug Chart Watch: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesGlobal Markets & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Is NeuroSense Therapeutics Ltd. Equity Warrant forming a bullish divergenceWeekly Trade Summary & Weekly Chart Analysis and Guides - mfd.ru
Wall Street Recap: How do insiders feel about Prelude Therapeutics IncorporatedQuarterly Performance Summary & Free High Return Stock Watch Alerts - baoquankhu1.vn
MACD Signal: Whats the fair value of NeuroSense Therapeutics Ltd stockAnalyst Upgrade & Weekly Momentum Picks - baoquankhu1.vn
Is NeuroSense Therapeutics Ltd. Equity Warrant stock recession proof2025 Performance Recap & High Return Trade Opportunity Guides - mfd.ru
Neurosense Therapeutics stock rises after securing Australian patent for PrimeC - Investing.com Nigeria
NeuroSense Wins Australian Patent to Extend PrimeC IP Protection Through 2042 - TipRanks
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition - Nasdaq
Does NeuroSense Therapeutics Ltd. Equity Warrant have strong fundamentalsJuly 2025 Weekly Recap & Consistent Profit Alerts - mfd.ru
How interest rate cuts could boost NeuroSense Therapeutics Ltd. stock2025 Major Catalysts & Free Fast Entry Momentum Trade Alerts - mfd.ru
Fund Flows: Can VTLE disrupt its industryQuarterly Market Review & Weekly Hot Stock Watchlists - baoquankhu1.vn
Market Rankings: Is NeuroSense Therapeutics Ltd Equity Warrant part of any ETFQuarterly Portfolio Report & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Is now the right time to enter Tectonic Therapeutic IncMarket Growth Report & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Buyback Watch: Is HSDT a play on infrastructure spending2025 Volume Leaders & AI Powered Market Trend Analysis - baoquankhu1.vn
Insider Buy: Is SPGPRJ undervalued by DCF analysisJuly 2025 Price Swings & Weekly High Momentum Picks - baoquankhu1.vn
Aug Retail: Will TILE benefit from seasonality2025 Valuation Update & Daily Growth Stock Tips - baoquankhu1.vn
Short Covering: Can SNVPRE expand into new marketsOil Prices & Verified Momentum Stock Watchlist - baoquankhu1.vn
Breakouts Watch: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buying2025 Winners & Losers & Reliable Momentum Entry Alerts - baoquankhu1.vn
Valuation Update: What is DMACs revenue forecastEarnings Overview Report & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
NeuroSense’s ALS drug PrimeC shows success in phase 2b, eyes final trial - MSN
Neurosense Therapeutics Ltd Stock (NRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):